openPR Logo
Press release

Introducing Netarsudil Impurity 15: Advancing Research and Quality Control in Ophthalmic Drug Development

07-10-2025 02:28 PM CET | Health & Medicine

Press release from: Aquigen Bio Sciences

Introducing Netarsudil Impurity 15: Advancing Research

Aquigen BioSciences, a leading name in pharmaceutical reference standards, is proud to announce the availability of Netarsudil Impurity 15. This latest addition to our comprehensive Netarsudil impurity standards portfolio supports pharmaceutical companies and research institutions in advancing the analytical evaluation and quality control of Netarsudil-based formulations.

Netarsudil, a Rho kinase inhibitor, is widely used in the treatment of open-angle glaucoma and ocular hypertension. As drug regulators globally tighten quality benchmarks for ophthalmic APIs and finished dosage forms, access to structurally characterized impurities like Netarsudil Impurity 15 is vital for accurate impurity profiling and method validation.

Why Netarsudil Impurity 15 Matters
Explore : https://aquigenbio.com/product/netarsudil-impurity-15/

Impurity profiling plays a critical role in pharmaceutical development, ensuring drug safety, efficacy, and compliance with international regulatory guidelines such as those set forth by ICH, USFDA, and EMA. Netarsudil Impurity 15 is a structurally identified and certified impurity that helps researchers and manufacturers:
Accurately quantify and qualify trace levels of process- or degradation-related impurities in Netarsudil formulations.

Conduct forced degradation studies and stability analysis.
Validate analytical methods such as HPLC, LC-MS/MS, and NMR spectroscopy.
Meet regulatory expectations for impurity thresholds and control strategies.

As impurity levels exceeding the threshold limits can affect therapeutic efficacy or even introduce toxicity, having a certified impurity standard like Netarsudil Impurity 15 is indispensable in drug lifecycle management.

Key Features of Netarsudil Impurity 15
Chemical Name: Netarsudil Impurity 15
Molecular Formula: Detailed structure available upon request
Purity: ≥98% (by HPLC)
Certificate of Analysis (CoA): Supplied with each batch, including spectral data (1H-NMR, Mass, IR)
Storage Conditions: Recommended to store under controlled room temperature
Application: Analytical R&D, impurity profiling, stability studies, regulatory submissions

Comprehensive Netarsudil Impurity Portfolio

At Aquigen BioSciences, we understand that each impurity tells a story about the drug's origin, stability, and synthetic process. That's why we offer an extended range of impurities beyond Netarsudil Impurity 15, including:

1. Netarsudil Amino Acid Impurity
Explore : https://aquigenbio.com/product/netarsudil-amino-acid-impurity/

This impurity arises from amino acid-based intermediates during the synthesis of Netarsudil. It is especially critical during process validation stages when route optimization is still underway. Utilizing this impurity allows researchers to track and reduce amino acid-related side reactions and maintain API purity at a consistently high level.

2. Netarsudil Boc Aminoisoquinoline Impurity
Explore : https://aquigenbio.com/product/netarsudil-boc-aminoisoquinoline-impurity/

Often seen in early intermediates or during incomplete Boc deprotection, this impurity reflects potential synthesis anomalies. By monitoring the Netarsudil Boc Aminoisoquinoline Impurity, formulation scientists can refine reaction conditions and eliminate undesired side-products, ultimately enhancing the safety profile of the final drug product.

Each of these impurities comes with a full Certificate of Analysis (CoA), enabling robust impurity quantification and facilitating method validation for regulatory filing.

Complying with Global Regulatory Expectations
Regulatory bodies such as the ICH require that all impurities above 0.05% (for APIs with a maximum daily dose below 2 g) be identified and qualified. The availability of authentic reference standards such as Netarsudil Impurity 15 ensures that:
Quality-by-Design (QbD) approaches are met during formulation and process development.

Accurate impurity mapping leads to better process understanding.

Formulators can establish impurity thresholds in compliance with regulatory expectations.

By using high-purity, well-characterized impurity standards from Aquigen BioSciences, pharmaceutical companies can significantly reduce the risk of regulatory rejections and improve drug dossier acceptance timelines.

Applications in Analytical R&D and Quality Control
The importance of impurity standards extends across multiple departments in a pharma company. From early-phase development to commercial manufacturing, Netarsudil Impurity 15 serves various functions:
Stability Testing: Evaluate how Netarsudil behaves under stress (light, heat, pH) and identify degradation pathways.

Method Validation: Validate chromatographic methods by establishing LOD/LOQ levels and specificity against known impurities.

Batch Release Testing: Ensure each batch conforms to predefined impurity limits before release to the market.

Our impurity standards are compatible with a range of analytical techniques, including but not limited to:
High-Performance Liquid Chromatography (HPLC)
Ultra Performance Liquid Chromatography (UPLC)
Mass Spectrometry (MS)
Nuclear Magnetic Resonance (NMR)
Infrared (IR) Spectroscopy

Explore Our Netarsudil Impurity Standards
https://aquigenbio.com/products/impurity-standards/netarsudil/

Our Netarsudil impurity standards category is continuously expanding to meet the needs of modern pharma R&D and regulatory environments. Whether you're working on generic development, biosimilar formulation, or NDA submission, Aquigen BioSciences is your go-to partner for high-purity impurity reference standards.

Contact:
Aquigen Bio Sciences
281/1, Plot No 41,
Hinjawadi - Pirangut Rd,
Kasar Amboli, Pirangut,
Pune, Maharashtra 412108
Phone: +91 7030123794
Email: bd@aquigenbio.com
Visit: www.aquigenbio.com

About Aquigen BioSciences?
Aquigen BioSciences has carved a niche in offering high-quality, pharmacopeial and non-pharmacopeial impurity standards across therapeutic categories. Our state-of-the-art R&D center and in-house synthesis capabilities enable us to deliver:
Extensive Inventory of reference impurities and APIs
Custom Synthesis support for client-specific impurities
Regulatory-Compliant Documentation, including CoAs, MSDS, and spectral data
Fast Turnaround and global shipping

By choosing Aquigen, customers benefit from reliability, scientific excellence, and a partnership rooted in quality.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Introducing Netarsudil Impurity 15: Advancing Research and Quality Control in Ophthalmic Drug Development here

News-ID: 4099485 • Views:

More Releases from Aquigen Bio Sciences

Estradiol Valerate EP Impurity A - Premium Reference Standard for Analytical Development, Quality Control, and Regulatory Compliance in Pharmaceutical Research
Estradiol Valerate EP Impurity A - Premium Reference Standard for Analytical Dev …
Estradiol Valerate EP Impurity A is a high-quality reference standard designed to meet the stringent requirements of pharmaceutical research, method validation, and quality control processes. Explore Estradiol Valerate EP Impurity A : https://aquigenbio.com/product/estradiol-valerate-ep-impurity-a/ Manufactured and characterized with precision, this impurity standard supports laboratories and manufacturers in achieving consistent, reliable, and reproducible results in critical analytical workflows. With its exceptional purity and accurate characterization, Estradiol Valerate EP Impurity A plays a vital role
High-Purity N-Nitroso Betahistine D3 for Precise Pharmaceutical Analysis | Deuterated Nitrosamine Impurity Standard for Method Development, Validation, Quality Control, and Regulatory Submissions in Betahistine Impurity Profiling and Research
High-Purity N-Nitroso Betahistine D3 for Precise Pharmaceutical Analysis | Deute …
Product Overview N-Nitroso Betahistine D3 is a premium deuterated nitrosamine impurity standard, specifically developed for precise analytical testing in pharmaceutical laboratories. This reference standard is widely used for analytical method development, validation, and quality control processes to meet stringent regulatory guidelines. With exceptional purity, complete documentation, and reliable traceability, it is ideal for research, development, and compliance applications. https://aquigenbio.com/product/n-nitroso-betahistine-d3/ Key Features and Benefits Deuterated Design for Precision: The incorporation of deuterium improves mass spectrometric
Aquigen Bio Strengthens Pharmaceutical Research with High-Purity Icatibant Impurity Standards
Aquigen Bio Strengthens Pharmaceutical Research with High-Purity Icatibant Impur …
Aquigen Bio, a trusted supplier of pharmaceutical reference standards, today announced the expansion of its Icatibant Impurity Standards portfolio, designed to support drug developers, analytical laboratories, and research organizations with reliable materials for impurity profiling and quality control. Icatibant, a selective bradykinin B2 receptor antagonist, is widely used in the treatment of hereditary angioedema (HAE). Given its peptide-based structure, Icatibant is prone to the formation of impurities during synthesis and storage.
Elevating Analytical Precision with Harmine Impurity Standards
Elevating Analytical Precision with Harmine Impurity Standards
In the realm of pharmaceutical research, controlling the purity of compounds is pivotal. When evaluating psychoactive alkaloids such as harmine-a β-carboline alkaloid known for its reversible monoamine oxidase A inhibition and emerging therapeutic potential-accuracy is non-negotiable. This is where Aquigen Bio Sciences brings its edge: supplying high-grade impurity standards to underpin analytical consistency and regulatory compliance. Why Harmine Impurity Standards Matter https://aquigenbio.com/products/impurity-standards/harmine/ Harmine occurs naturally in Peganum harmala and Banisteriopsis caapi, and has

All 5 Releases


More Releases for Netarsudil

Fuchs Endothelial Corneal Dystrophy Market Insights Highlight Expanding Outlook …
DelveInsight's "Fuchs Endothelial Corneal Dystrophy Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Fuchs Endothelial Corneal Dystrophy, historical and forecasted epidemiology as well as the Fuchs Endothelial Corneal Dystrophy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Fuchs Endothelial Corneal Dystrophy market outlook, drug uptake, treatment scenario and epidemiology trends, Click
Fuchs Endothelial Corneal Dystrophy Market Forecasted to Surge in Coming Years, …
DelveInsight's "Fuchs Endothelial Corneal Dystrophy Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Fuchs Endothelial Corneal Dystrophy, historical and forecasted epidemiology as well as the Fuchs Endothelial Corneal Dystrophy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Fuchs Endothelial Corneal Dystrophy market outlook, drug uptake, treatment scenario and epidemiology trends, Click
Fuchs Endothelial Corneal Dystrophy Market to Reach New Heights in Growth by 203 …
DelveInsight's "Fuchs Endothelial Corneal Dystrophy Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Fuchs Endothelial Corneal Dystrophy, historical and forecasted epidemiology as well as the Fuchs Endothelial Corneal Dystrophy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Fuchs Endothelial Corneal Dystrophy market outlook, drug uptake, treatment scenario and epidemiology trends, Click
Fuchs Endothelial Corneal Dystrophy Market Forecasted to Surge in Coming Years, …
The Key Fuchs Endothelial Corneal Dystrophy Companies in the maret include - ProQR Therapeutics, Kowa Pharmaceuticals, Trefoil Therapeutics, Alcon Inc., Emmecell, Santen and ActualEye, Price Vision Group, Santen Inc., Aerie Pharmaceuticals, and others DelveInsight's "Fuchs Endothelial Corneal Dystrophy Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Fuchs Endothelial Corneal Dystrophy, historical and forecasted epidemiology as well as the Fuchs Endothelial Corneal Dystrophy market trends in the
Fuchs Endothelial Corneal Dystrophy Pipeline Update 2024: FDA Approvals, Therape …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Fuchs Endothelial Corneal Dystrophy pipeline constitutes 5+ key companies continuously working towards developing 5+ Fuchs Endothelial Corneal Dystrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Fuchs Endothelial Corneal Dystrophy Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across
Fuchs Endothelial Corneal Dystrophy Market 2034: Epidemiology Analysis, Therapeu …
DelveInsight's "Fuchs Endothelial Corneal Dystrophy Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Fuchs Endothelial Corneal Dystrophy, historical and forecasted epidemiology as well as the Fuchs Endothelial Corneal Dystrophy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Fuchs Endothelial Corneal Dystrophy market outlook, drug uptake, treatment scenario and epidemiology trends, Click